I choose to invest in Novavax, Inc for a couple of reasons. Novavax, Inc is a biopharmaceutical company that is involved in creating vaccines and vaccine adjuvants to address a broad range of infectious diseases worldwide.
Have you heard of the respiratory syncytial virus (RSV)?
RSV is a disease that affects the respiratory tract of many children and the elderly, leading to pneumonia, bronchitis, and recurrent wheezing. Although, it is usually self-limiting and will go away on its own, there are approximately 3.4 million severe cases of hospital admissions per year globally leading to 160,000 deaths and yet there is currently no approved RSV vaccine.
Novavax, Inc is now in phase 1 clinical trial of RSV vaccine. A vaccine can help decrease the need for frequent medical care, including ER and physician office visits.
Moreover, the market cap is around 1.27 billion, which meets my criteria of smaller market cap stocks, as they are my favourite in creating value quickly. It is traded on Nasdaq with an average volume of 5 million and is not a penny stock that you might get stuck on when trying to exit.
Lastly, the stock price is currently at $5.24 that makes it affordable for small investors like myself.
No comments:
Post a Comment